Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83.

View in: PubMed

subject areas

Adult
Aged
Analysis of Variance
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Female
Humans
Immunohistochemistry
Induction Chemotherapy
Magnetic Resonance Imaging
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Staging
Predictive Value of Tests
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies
Sensitivity and Specificity
Treatment Outcome

authors with profiles

Rita Nanda